{"@context":{"@vocab":"https://schema.org/","dcterms":"http://purl.org/dc/terms/","prov":"http://www.w3.org/ns/prov#"},"@type":"ItemList","@id":"https://api.morvs.ai/api/v1/entity/EBS/timeline","_source":{"data_provider":"AI Analytics","brand_name":"MORVS","brand_url":"https://morvs.ai/","data_provider_url":"https://api.morvs.ai","license":"https://api.morvs.ai/license","usage_info":"https://api.morvs.ai/license","rights":"Source-specific terms apply; free or keyless access does not alter them.","generated_at":"2026-10-08T05:51:24.094Z","methodology_url":"https://api.morvs.ai/datasets/","primary_sources":{"sec.*":"https://www.sec.gov/edgar","fda.*":"https://api.fda.gov/","contracts":"https://api.usaspending.gov/","clinical.trials":"https://clinicaltrials.gov/","lobbying.filings":"https://lda.senate.gov/","epa.facilities":"https://echo.epa.gov/","court.dockets":"https://www.courtlistener.com/","cfpb.complaints":"https://www.consumerfinance.gov/data-research/consumer-complaints/","nih.grants":"https://api.reporter.nih.gov/","fed.enforcement":"https://www.federalreserve.gov/supervisionreg/enforcementactions.htm","nhtsa.recalls":"https://api.nhtsa.gov/recalls/"}},"entity":{"entity_id":6372,"canonical_name":"Emergent BioSolutions Inc.","cik":"0001367644","uei":null,"lei":null,"duns":null,"ticker":"EBS"},"window_days":180,"min_importance":0,"sources_queried":["sec.filings","sec.insider","sec.form144","sec.13dg","fda.recalls","fda.labels","contracts","clinical.trials","lobbying.filings","epa.facilities","uspto.patents","court.dockets","cfpb.complaints","nih.grants","fed.enforcement","nhtsa.recalls","doj.press","dol.form5500"],"importance_reference":{"fda.recall Class I":100,"clinical trial terminated":80,"securities class action":80,"antitrust suit":75,"schedule 13D":75,"patent litigation":70,"form144 large ($50M+)":75,"10-K restatement":75,"phase3 trial completed":70,"EPA significant violator":70,"phase3 trial in progress":60,"insider purchase":50,"phase2 trial":45,"8-K":35,"lobbying filing":30,"fda.label":30,"phase1 trial":30,"fda.recall Class III":25},"vertical_counts":{"sec":13,"clinical":2},"count":15,"timeline":[{"ts":"2026-07-02","kind":"sec.filing","form_type":"4","title":"4 — Emergent BioSolutions Inc. — 2026-07-02","url_slug":"/sec/cik-0001367644/4/0001961994-26-000024","accession_number":"0001961994-26-000024","importance":30},{"ts":"2026-07-01","kind":"sec.form144","reporter":"PAUL WILLIAMS","title":"Officer","shares":3000,"usd_value":25205,"security_title":"Common","approx_sale_date":"2026-07-01","accession_number":"0001950047-26-006683","importance":40.00504108},{"ts":"2026-07-01","kind":"sec.insider.s","reporter":"Williams Paul Anthony","title":"SVP, Products Business","shares":3000,"price_per_share":8.4,"usd_value":25200,"security_title":"Common Stock","importance":35.0252},{"ts":"2026-07-01","kind":"sec.filing","form_type":"144","title":"144 — Emergent BioSolutions Inc. — 2026-07-01","url_slug":"/sec/cik-0001367644/144/0001950047-26-006683","accession_number":"0001950047-26-006683","importance":30},{"ts":"2026-06-29","kind":"sec.filing","form_type":"8-K","title":"8-K — Emergent BioSolutions Inc. — 2026-06-29","url_slug":"/sec/cik-0001367644/8-k/0001367644-26-000068","accession_number":"0001367644-26-000068","importance":35},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — Emergent BioSolutions Inc. — 2026-06-10","url_slug":"/sec/cik-0001367644/4/0001919170-26-000016","accession_number":"0001919170-26-000016","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — Emergent BioSolutions Inc. — 2026-06-10","url_slug":"/sec/cik-0001367644/4/0001961994-26-000021","accession_number":"0001961994-26-000021","importance":30},{"ts":"2026-06-10","kind":"sec.filing","form_type":"4","title":"4 — Emergent BioSolutions Inc. — 2026-06-10","url_slug":"/sec/cik-0001367644/4/0001989644-26-000011","accession_number":"0001989644-26-000011","importance":30},{"ts":"2026-06-08","kind":"sec.insider.f","reporter":"LINDAHL RICHARD S","title":"EVP, Chief Financial Officer","shares":3964,"price_per_share":8,"usd_value":31712,"security_title":"Common Stock","importance":15.031712},{"ts":"2026-06-08","kind":"sec.insider.f","reporter":"Glessner Coleen","title":"EVP, Quality & Ethics, and CPL","shares":2018,"price_per_share":8,"usd_value":16144,"security_title":"Common Stock","importance":15.016144},{"ts":"2026-06-08","kind":"sec.insider.f","reporter":"Hartzel William","title":"SVP, Bioservices","shares":1741,"price_per_share":8,"usd_value":13928,"security_title":"Common Stock","importance":15.013928},{"ts":"2026-06-08","kind":"sec.insider.f","reporter":"Williams Paul Anthony","title":"SVP, Products Business","shares":694,"price_per_share":8,"usd_value":5552,"security_title":"Common Stock","importance":15.005552},{"ts":"2026-05-12","kind":"clinical.trial","reporter":"Emergent BioSolutions","title":"VA-005 Clinical Outcomes of VIGIV Treatment of Smallpox Vaccination Complications or Vaccinia Infection","security_title":null,"status":"ENROLLING_BY_INVITATION","accession_number":"NCT01374984","excerpt":"[\"Complication of Smallpox Vaccination\"]","importance":25},{"ts":"2026-04-27","kind":"sec.filing","form_type":"DEFA14A","title":"DEFA14A — Emergent BioSolutions Inc. — 2026-04-27","url_slug":"/sec/cik-0001367644/defa14a/0001193125-26-182326","accession_number":"0001193125-26-182326","importance":30},{"ts":"2026-04-15","kind":"clinical.trial","reporter":"Emergent BioSolutions","title":"Pharmacokinetics (PK) and Safety of Multiple Doses of Intranasal Naloxone in Healthy Adults","security_title":"PHASE1","status":"COMPLETED","accession_number":"NCT05377255","excerpt":"[\"Opioid Overdose\"]","importance":30}]}